First Results of Avicidin Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation studies, Avicidin produced a 10-fold improvement in tumor-to-blood ratios over conventional radioimmunotherapy, approaching the ratios achieved in animal studies.

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalationstudies, Avicidin produced a 10-fold improvement in tumor-to-bloodratios over conventional radioimmunotherapy, approaching the ratiosachieved in animal studies.

Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx'sproprietary pretargeting technology in which the radionuclideand antibody are injected separately rather than linked together.The radionuclide either attaches to the antibody that is pretargetedto the tumor or quickly exits the body, reducing radiation exposureto normal tissues, NeoRx said.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content